Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

023 - A Broadway Performance Analogy for API Process Validations with Jim Mencel

023 - A Broadway Performance Analogy for API Process Validations with Jim Mencel

FromCMC Live - Chemistry, Manufacturing & Controls


023 - A Broadway Performance Analogy for API Process Validations with Jim Mencel

FromCMC Live - Chemistry, Manufacturing & Controls

ratings:
Length:
44 minutes
Released:
Feb 26, 2021
Format:
Podcast episode

Description

What We Covered00:52 – Ed, Meranda and Brian welcome back Jim Mencel who shares his extensive experience with process validation07:46 – The importance of Proven Acceptable Range (PAR) and Critical Process Parameter Program (CPP)  11:14 – The evolution of the batch documentation and the value of critical parameter studies  18:07 – Registration laws and gathering necessary stability data  20:49 – How validation material can be used for launch  24:15 – Jim speaks to the importance of writing a Protocol and having a quality supplier team  32:34 – Jim discusses timing when moving towards validation  38:02 – Jim reinforces the notion that communication is key when it comes to process validation  40:42 – Final recommendations Jim would give regarding process validation  Tweetable Quotes“Validation’s very formal. Validation really, in a stage analogy, is Opening Night. This is where the critics are all present, everybody’s breathing on you, you’re gonna be in the headlines the next day and everything needs to go right. So, when you think about it in that context, the validation batches are very visible to regulatory authorities.”“Your batch record really is a document that’s going to evolve. And if you look at the batch record for even the same step of a process, what that’s going to look like when you’re in the early phases of clinical development is different from what it’s going to look like towards the end. It’s going to be much more refined.”“There is a point where the process is the process. And as inefficient as it may be, it’s what you have.” “Yes, your validation batches certainly count as launch stock as long as they pass all specs.” “When you go into validation, you’ve gotta have your suppliers identified. And quality plays a huge role in assessing your suppliers” “What it all comes down to is that preparing for the validation is something that you should be thinking about as you’re making your later clinical batches, your Phase 2 batches especially.”“When you’re in Phase Three it’s not a place to be penny-pinching. The old saying is, ‘you drive for show, you put for dough.’ When you’re validating, you’re putting for dough.” Relevant LinksDesign Space InPharmatics – LinkedInDesign Space InPharmatics – TwitterEdward Narke on LinkedInJim Mencel on LinkedIn
Released:
Feb 26, 2021
Format:
Podcast episode

Titles in the series (27)

FDA CMC regulations and guidance simplified through examination, real life experiences and risk-based advice. This podcast hopes to educate sponsors and individuals on agency related regulatory CMC matters. We will focus on the critical CMC issues and build programs that enhance drug development. CMC topics will include Regulatory Starting Materials, API and Drug Product Process, Formulation Development, Supply Chains, Analytical Controls. Advocating and interpreting CMC Strategy, directing CMC Operations and Quality Assurance oversight in conjunction with developing CMC submission content that represents the best interests of emerging biotech. NOT INTENDED TO BE PRESCRIPTIVE ADVICE BUT RATHER INTERPRETATION THAT IS RIGHT FOR YOU. Since 2007 we have provided our partners with innovative strategies and exceptional advice intended to enhance program development, product approval, and marketing presence.